Newstral
IPR
- No Attorneys’ Fees Available for Successful IPR in Parallel Court Proceedingsjdsupra.com
- Patent Infringement Suit Against Indemnitee Forecloses IPR Petition by Indemnitorjdsupra.com
- Federal Circuit Finds Application of Printed Matter Doctrine Too Expansivejdsupra.com
- IP Alert: USPTO Proposes New Rules for AIA Trial Practicejdsupra.com
- Navigating Revised Motions to Amend in Inter Partes Review as a Non-active, Joined Partyjdsupra.com
- Citizen scientists can help count planter pollinators in northern Michiganmetrotimes.com
- PTAB Denies IPR Petition for Failure to Construe Claimsjdsupra.com
- Federal Circuit Confirms Boundaries of Fee Recovery Under 35 USC § 285jdsupra.com
- En Banc Federal Circuit Overrules Longstanding Test for Design Patent Obviousnessjdsupra.com
- How Are The USPTO’s Proposed Rule Changes For Terminal Disclaimers Problematic?: Let Me Count The Waysjdsupra.com
- LKQ v. GM: What In-House Counsel Needs to Know About This Change in Design Patent Lawjdsupra.com
- Federal Circuit Patent Watch: Section 285 Does Not Extend to Recovery of IPR Feesjdsupra.com
- FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon’s Yesafili™ (aflibercept-jbvf) and Samsung Bioepis’s Opuviz™ (aflibercept-yszy)jdsupra.com
- Protective Order Forecloses Participation of Litigation Counsel in Motion to Amend Process Before the PTABjdsupra.com
- Canadian wildfire smoke just blanketed the Midwest — againmetrotimes.com
- Termination of IPR Proceeding on the Eve of Final Written Decision Dooms Joinder Attemptjdsupra.com
- Say What? Recitation Entitled to Patentable Weight When Not “Communicative Content”jdsupra.com
- Institution Denied For Lack of Sufficient Structurejdsupra.com
- Alexion’s Preliminary Injunction Motion Denied in Eculizumab BPCIA Litigation Against Samsung Bioepisjdsupra.com
- Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant® (trastuzumab-dttb) / Trazimera® (trastuzumab-qyyp) / Kanjinti® (trastuzumab-anns) / Hercessi™ (trastuzumab-strf)jdsupra.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.